arylsulfatase activity was demonstrated in patients with deletions spanning the CDPX region. These data indicate that CDPX is caused by an inherited deficiency of a novel sulfatase and suggest that warfarin erabryopathy might involve drug-induced inhibition of the same enzyme.
Introduction
The sulfatases are a group of enzymes that hydrolyze sulfate ester bonds in a wide variety of structurally different compounds, ranging from complex molecules, such as glycosaminoglycans and sulfolipids, to 31B-hydroxysteroid sulfates (Ballabio and Shapiro, 1995) . Nine different human sulfatases have been described and characterized biochemically (for reviews see Ballabio and Shapiro, 1995; Kolodny and Fluharty, 1995; Neufeld and Muenzer, 1995) . The importance of these proteins in human metabolism is emphasized by the presence of seven distinct inherited disorders resulting from specific sulfatase deficiencies (Kolodny and Fluharty, 1995; Neufeld and Muenzer, 1995) .
The evidence that sulfatases are members of a family of related proteins, probably sharing acom mon ancestor, is both structural and functional. The cloning and sequencing of six human sulfatase cDNAs (Ballabio et al., 1987; Yen et al., 1987; Robertson et al., 1988; Stein et al., 1989a; Peters et al., 1990; Schuchman et al., 1990; Wilson et al., 1990; Tomatsu et al., 1991) , of a sea urchin arylsulfatase cDNA (Sasaki et al., 1988) , and of Escherichia coil (Daniels et al., 1992) and Klebsiella aerogenes (Murooka et al., 1990) arylsulfatases have revealed a high degree of homology along the entire length of these proteins, particularly in the N-terminal regions, suggesting that specific motifs in the amino acid sequence are important for sulfatase activity (Wilson et al., 1990) . Additional evidence that all sulfatases are functionally related comes from the study of a rare and intriguing genetic disease named multiple sulfatase deficiency (MSD), in which all known sulfatases are deficient (Kolodny and Fluharty, 1995) . This autosomal recessive disorder may be due to an abnormality in a posttranslational event common to all sulfatases. Three of the previously described human sulfatases, known as arylsulfatases A, B, and C (ARSA, ARSB, and ARSC), are able to hydrolyze sulfated artificial substrates containing a phenolic ring, such as p-nitrocatechol sulfate or 4-methylumbelliferyl sulfate (4-MU sulfate) (Kolodny and Fluharty, 1995) . ARSC is more specifically known as steroid sulfatase (STS) because of its ability to hydrolyze steroid sulfates. While ARSA, ARSB, and ARSC each act on a distinct natural substrate, they all have a "promiscuous" activity against artificial substrates (arylsulfatase activity). ARSA and ARSB are lysosomal in their subcellular localization and have acidic pH optima, while ARSC is microsomal and has a neutral to alkaline pH optimum (Ballabio and Shapiro, 1995) .
The term "chondrodysplasia punctata" refers to a group of skeletal dysplasias characterized by abnormal calcium deposition in regions of enchondral bone formation. This abnormality results in a peculiar radiological finding, commonly referred to as "stippling" of epiphyses or "paintspattered" calcifications. These calcifications tend to disappear within the first few years of life as bone development progresses. Chondrodysplasia punctata is heterogeneous both at the genetic and clinical levels, and only a few distinct entities with different patterns of inheritance and variable degrees of severity appear to be fairly well characterized (Spranger et al., 1970) . A specific type of chondrodysplasia punctata is associated with nullisomy of the distal short arm of the human X chromosome (Xp22.3) in males with deletions and translocations involving this region (Curry et al., 1984) . These patients have contiguous gene syndromes due to the involvement of adjacent disease genes on Xp22.3 (Ballabio and Andria, 1992) . Affected individuals display facial dysmorphism characterized by severe nasal hypoplasia, depressed nasal bridge, short nasal septum, and a deep groove between the nasal alae and the tip. They also have short stature and distal phalangeal hypoplasia, the latter being particularly evident by radiological examination. Punctate stippling of multiple epiphyseal centers is observed in the neonatal and early infancy periods and usually disappears with age. There is strong genetic evidence that this mild and rather distinct type of chondrodysplasia punctata, referred to as X-linked recessive chondrodysplasia punctata (CDPX; MIM302950), is due to the loss of function of a specific gene on Xp22.3 (for review see Ballabio and Andria, 1992) .
A phenotype clinically indistinguishable from that of CDPX has also been described in a few patients with no visible or molecularly detectable chromosomal abnormality (Sheffield et al., 1976; Maroteaux, 1989) . Although some of these patients may carry point mutations in the putative CDPX gene, as most of them lack a positive family history, the possibility of genetic heterogeneity for the CDPX phenotype should be considered.
Interestingly, CDPX shows remarkable phenotypic similarities to two well-characterized disease entities involving vitamin K metabolism and function: warfarin embryopathy and vitamin K epoxide reductase deficiency. Warfarin embryopathy is caused by the administration of warfarin, an anticoagulant drug, during a critical period of 6-9 weeks of pregnancy (for review see Hall et al., 1980) . Vitamin K epoxide reductase deficiency, also known as pseudowarfarin embryopathy, is a rare autosomal recessive disorder affecting the recycling of vitamin K (Pauli et al., 1987; Pauli, 1988) . Both of these disorders display abnormalities of cartilage and bone development that are strikingly similar to those observed in CDPX. The phenotypic similarities among CDPX, warfarin embryopathy, and vitamin K epoxide reductase deficiency suggest the possibility that genetic and drug-induced defects underlying thase syndromes may affect the same metabolic pathway.
Over 50 patients carrying deletions and translocations involving the Xp22.3 region and displaying features of CDPX have been described (for review see Ballabio and Andria, 1992) . Molecular genetic analysis of some of these patients has defined the critical genomic region that must contain the CDPX gene (Wang et al., 1995) . In this study, we report the isolation from this region of a cluster of genes showing a significant homology to all members of the sulfatase gene family. Point mutations in one of these genes, named arylsulfatase E (ARSE), were identified in five patients with CDPX, indicating that this disorder is caused by a sulfatase deficiency. Transfection of ARSE cDNA into COS cells results in an arylsulfatase activity that is inhibited bywarfarin, providing insight into the pathogenesis of warfarin embryopathy.
Results

Identification of Three Novel Sulfatase Genes on Xp22.3
In a recent study, we described the assignment of the CDPX gene to a specific genomic segment of 600 kb located approximately 150 kb centromeric to the pseudoautosomal boundary on Xp22.3 (Wang et al., 1995) . Overlapping yeast artificial chromosome (YAC) clones spanning this entire region were isolated and partially characterized. Two YAC clones, NB6F12 and 455B10, were purified by pulsed-field gel electrophoresis (PFGE) and hybridized to an arrayed X chromosome-specific cosmid library obtained from Lawrence Livermore laboratories, as previously described (Wapenaar et al., 1994) . Two groups of overlapping cosmid clones were identified and used in exon trapping experiments in order to identify candidate genes for CDPX (Figure 1 ). DNA from cosmids 18, 76, 75, 48, 32, 66, 58, 96 , and 100 was subcloned into the pSPL3 vector (Church et al., 1994) , and exon amplification products were blotted and hybridized to the corresponding cosmid DNA. Several putative exons were identified using this strategy and were characterized by reverse transcriptionpolymerase chain reaction (RT-PCR) using RNAs from several tissues (data not shown), by sequence analysis, and by hybridization to the DNA from patients BA169 and BA311. Five different exons were found to map back to the CDPX critical region and to be expressed based on RT-PCR. Their position with respect to YAC and cosmid clones from the region is shown in Figure 1 .
Sequence analysis of these five exons was determined, and nonredundant DNA and protein data bases were searched using the BLAST-X, BLAST-P, and TBLAST-N algorithms. Striking similarities were identified with all previously described members of the sulfatase gene family, including sulfatases from distantly related species such as bacteria. The highest homology scores for each of the five exons were with the STS (ARSC) sequence.
The relative position of the five exons in the cosmid map and the alignment with previously described sulfatase sequences (STS in particular) led us to conclude that these exons must be derived from at least two distinct genes. This was confirmed by subsequent cDNA identification and characterization. PCR products from exons 76. 15, 18.12, and 48.7 (Wang et al., 1995) . YAC clones are shown as thick bars. Closed circles show the position of single-copy probes used for YAC identification and for the assembly of the YAC contig. Thin bars indicate cosmid clones used for the exon amplification experiments. Putative exons are depicted as closed boxes. The position and orientation of transcription of the three novel sutfatase genes isolated from the region are shown at the bottom. The orientation of transcription of the ARSF gene is unknown. PABX, pseudoautosomal boundary on the X chromosome.
both transcripts. Owing to their high degree of homology with arylsulfatases and based on the results of functional analyses (see below), these two genes were named ARSD and ARSE. The orientation of transcription of the genes is centromere to telomere, as shown in Figure 1 . Both genes appear to have a single copy located in the Xp22.3 region. However, some cDNA fragments detect Y chromosome-specific bands by Southern blot analysis (data not shown). A detailed characterization of the genomic structure of the two genes will be reported elsewhere. Hybridization of cDNA probes to cosmid clones 18, 76, 75, and 48 (see Figure 1 ) from the CDPX critical region revealed that the two genes did not cross-hybridize to each other, with the exception of a small region in the vicinity of their 3' ends. Probes spanning this region of the cDNA also hybridized to cosmids 58 and 96, suggesting the presence of a third homologous gene. To investigate this hypothesis, cosmid 96 was digested with Sau3A and subcloned into a plasmid vector. Plasmid clones hybridizing to the cDNA clones were sequenced, and a region of high homology to sulfatase cDNAs was identified. This region of homology was flanked by consensus splice sequences, indicating that it corresponded to an exon. Preliminary data obtained by both RT-PCR and Northern blot analysis indicate that this exon belongs to a transcribed gene, which we named ARSF because of the extremely high degree of homology with ARSD and ARSE (Figure 2 ).
Analysis of ARSD and ARSE cDNA Sequences ARSD consensus cDNA sequence (1945 bp) was assembled by analysis of sequences from four cDNA clones and partly from the corresponding genomic clones. The authenticity of the 5' end was validated by 5'-RACE-PCR experiments and by sequencing the corresponding genomic region. The putative initiation codon was identified at position 77 and the first in-frame stop codon (TGA) at nucleotide 1856, resulting in a predicted protein of 594 amino acids. ARSE consensus cDNA sequence (1858 bp) was assembled from the analysis of 13 cDNA clones and of several exon-containing genomic clones. The authenticity of the 5' end was validated by comparing the sequence of several overlapping cDNA clones and by sequencing the corresponding genomic region. The putative initiation codon was identified at nucleotide 68, a polyadenylation site AATAA at position 1833, and the first in-frame stop codon at 1835, resulting in a predicted protein of 590 amino acids. Interestingly, this stop codon (TAA) is part of the polyadenylation site, resulting in an extremely short 3' untranslated region. Figure 2 shows the results of the alignment of the ARSD, ARSE, and ARSF predicted protein products with previously reported glucosamine-6-sulfatase (G6S), iduronate sulfatase (IDS), N-acetylgalactosamine-6-sulfatase (Gal6S), ARSA, ARSB, and ARSC/STS proteins. The homology is particularly high near the N-terminus, where a putative active site of some of these enzymes is thought to reside (Wilson et al., 1990) . A region with low amino acid identity, corresponding to a transmembrane domain in ARSC/STS (Stein et al., 1989b) , is found in G6S, IDS, ARSC/STS, ARSD, and ARSE and is absent in Gal6S, ARSA, and ARSB. The highest identity scores were found when comparing ARSD with ARSE and when comparing these two with ARSC/STS, indicating that these three genes are much more closely related to each other than to the other members of the family.
ARSD and ARSE Expression Pattern
Northern blot analysis of ARSD and ARSE mRNAs revealed different expression patterns for these two genes. ARSD cDNA probes detected both a 5 kb transcript and a much less abundant 3.5 kb transcript in pancreas, kidney, liver, lung, placenta, brain, and heart ( Figure 3A ). Pancreas and kidney showed relatively higher levels of expression. Under the same conditions, probes from the ARSE gene detect a very abundant 2.2 kb and a less abundant 4 kb transcript ( Figure 3B ). ARSE mRNA is much more abundant compared with ARSD ( Figures 3A and 3B have different exposure times) and appears to have a more discrete tissue distribution, being expressed exclusively in pancreas, liver, and kidney among all the tissues tested. Preliminary data indicate that the different forms of ARSD and ARSE transcripts are generated by the use of different polyadenylation sites, resulting in different lengths of the 3' untranslated region.
Detection of ARSD and ARSE mRNAs in cultured cell lines by RT-PCR allowed us to test the X-inactivation sta- tus of these two genes. Reverse-transcribed RNA samples from a male control and a hybrid cell line retaining the inactive X chromosome were amplified by PCR using oligonucleotide primers generated from the cDNA sequences. As shown in Figure 3C , both ARSD and ARSE mRNAs were detected in the male control and in the hybrid cell line, indicating that these genes are expressed by both the active and the inactive X chromosomes, thus escaping X-inactivation. (C) X inactivation studies of ARSD and ARSE genes. Oligonucleotide primers from ARSD and ARSE cDNAs were used for the amplification of reverse-transcribed total RNA from a normal male fibroblast cell line (XY), from a human/hamster hybrid cell line retaining the human inactive X chromosome (Xi), and from a hamster cell line. Plus and minus indicate presence and absence of reverse transcriptase in the RT reaction. ARSD and ARSE primers amplify a 148 bp and a 450 bp product, respectively, from both the active and inactive X chromosome (left panels). As controls, oligonucleotide primers from MIC2 gene, known to escape X inactivation, and PGK1 gene that is expressed only by the active X chromosome were used to amplify the same templates (right panels).
Searching for Mutations in
patients. To test for the presence of point mutations, the sequence of most intron-exon boundaries of both ARSD and ARSE genes was determined, and oligonucleotide primers were generated to amplify single exons. Amplified exons were tested by single strand conformation polymorphism (SSCP), and several band mobility shifts were identified. Each of the exons in which a band mobility shift was identified was tested by SSCP on 60 female controls (a total of 120 normal X chromosomes) to exclude a polymorphisrn. A total of 4 out of 10 exons were tested for ARSD and 9 out of 11 exons for ARSE. Five unrelated patients (PAR492, PAR484, BA439, BA440, and NAN514) were found to have a band mobility shift in ARSE exons not present in any of the controls, in all five cases, missense mutations were identified by direct sequence analysis using oligonucleotides from the flanking introns. Types and positions of the mutations are listed in Table 1 . The absence of these mutations in 120 normal X chromosomes suggests that they are responsible for CDPX. Figure 4 shows the sequence analysis of exon 4 of the ARSE gene in patient PAR492 in whom the G137V mutation was identified. This mutation is of particular interest, since the Gly at position 137 is conserved in all sulfatases and a mutation in the ARSB gene causing an identical amino acid substitution has been described in a patient with mucopolysaccharidosis VI ( M a r o t e a u x -L a m y syndrome) (Wicker et al., 1991) .
Biochemical Characterization of ARSE Gene Product in COS Cells
Transient expression of ARSE in COS cells was obtained by subcloning the cDNA in the pcDL-SRe296 vector (Takebe et al., 1988) . As negative controls, COS cells were also transfected in parallel with vector alone and with a construct carrying the ARSE cDNA in the antisense orientation. Expression of the ARSC/STS cDNA, subcloned in the same vector, was performed in parallel for comparison. The results of enzymatic determinations performed at neutral pH using COS cell extracts 48-76 hr after transfection are shown in Table 2 . They indicate that the ARSE gene product is an arylsulfatase, as demonstrated by the 6-to 8-fold increase of enzymatic activity observed when 4-MU sulfate was used as a substrate. Unlike ARSC/STS, ARSE has no activity toward steroid sulfates such as dehydroepi- Table 1 
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WT AAA[~ATGCCACTGGAC P AAA~ATGCCACTGGAC VAL Figure 4 . Sequence Analysis of the G137V Mutation Genomic DNA from patient PAR492 (P) and from a normal individual (WT) was amplified using primers flanking exon 4 (see Table 1 ) and sequenced. Sequencing reactions were loaded in the following order: A, C, G, T. The arrows indicate the position of the G to T transversion. A comparison between patient and wild-type sequences in the region where the G137V mutation is located is shown at the bottom.
androsterone sulfate (DHEAS) and estrone sulfate (ES). ARSE activity can be distinguished from ARSC since it is not competitively inhibited by DHEAS ( Figure 5A ) and is more heat labile ( Figure 5B ).
ARSE Is Inhibited by Warfarin
Because of the phenotypic similarities of CDPX and warfarin embryopathy, we speculated that warfarin might interfere with ARSE activity. Figu re 5C shows ARSE and ARSC activities in transfected COS cells in the presence of increasing warfarin concentrations. A significant decrease of ARSE activity was observed starting at concentrations between 10 and 50 p.M and reaching a complete inhibition at 5 mM. ARSC activity remained constant even at the highest warfarin concentrations. These data indicate that ARSE is inhibited by warfarin.
Arylsulfatase Activity in CDPX Based on the above described data, one would expect that patients with CDPX lack an arylsulfatase activity that is biochemically distinct from the other arylsulfatases. To test this hypothesis, we have developed a specific assay to measure ARSE activity in fibroblasts from these patients. A major problem in developing such a test is the interference of ARSC activity at neutral pH. Therefore, the enzymatic assay was run in the presence of DHEAS, a natural substrate of ARSC/STS protein, which competitively inhibits ARSC. Under these conditions, approximately 70%-90% of the measurable arylsulfatase activity is heat labile. Figure 6 shows the results of enzymatic assays performed in control and patient fibroblasts. The heat-labile arylsulfatase activity ranged from 350-850 pmol/mg/hr in six control cell lines and in fibroblasts from four patients with isolated X-linked ichthyosis (BA65, BA67, BA88, and BA16) who have a deletion of the ARSC/ STS gene. This heat-labile enzymatic activity represents a tiny portion of the total neutral arylsulfatase activity and, therefore, can be easily overlooked under the assay conditions commonly used for ARSC measurement. We have , Activities expressed as nmoles/mg/hr, b Activities expressed as pmoles/mg/hr. tested fibroblasts from a patient (BA311) with a deletion of the CDPX critical region and from three patients (BA20, BA424, and BA423) with large Xp22.3 deletions spanning both the CDPX critical region and the ARSC/STS gene (Schaefer et al., 1993) . In all of these patients, as well as in two patients with MSD (BA426 and BA428), we have found a profound deficiency of a heat-labile DHEASresistant arylsulfatase activity. Cell line BA311 has a complete deficiency of a heat-labile arylsulfatase activity, while both ARSC and STS activities are normal. Conversely, in patients affected by isolated X-linked ichthyosis, heatlabile arylsulfatase activity is normal (Figure 6 ).
The combination of these results points to the existence of a neutral arylsulfatase activity that is deficient in patients with deletions of the CDPX critical region and is distinct from ARSC. Genetic and biochemical data indicate that this neutral arylsulfatase is the product of the ARSE gene. However, we cannot exclude the possibility that ARSD and ARSF gene products may contribute to this activity. Biochemical characterization of ARSD and ARSF gene products and the study of patients with point mutations in the ARSE gene might help to clarify this issue. Unfortunately, flbroblasts from these patients are not available at this time.
Discussion
A Cluster of Sulfatase Genes on Xp22.3
We have identified three novel genes on the X chromosome sharing homology with all members of the sulfatase gene family: ARSD, ARSE, and ARSF. Unlike all other members of this family, these genes were isolated by positional cloning, a strategy that does not rely on the knowledge of the gene product. This approach often leads to the discovery of novel metabolic pathways that had not been predicted by classical biochemical studies.
ARSD, ARSE, and ARSF are positioned in tandem in a small region on Xp22.3. Sequence and structural similarities among these genes suggest that they were generated by ancient duplications. Duplications are not unprecedented in this region of the human genome. For example, evidence has been presented that tandem duplications in the pseudoautosomal region resulted in the presence of (B) Time course of heat inactivation of ARSE. COS cell extracts were incubated at 50°C for the times indicated and used for neutral arylsulfatase activity determinations. ARSE activity was almost completely inactivated within 10 rain of incubation at 50°C, while ARSC activity remained constant after incubation times up to 60 rain. (C) Warfarin inhibition of ARSE. Neutral arylsulfatase assay was run in the presence of increasing concentrations of warfarin. The average values of three separate measurements and the standard deviations are shown. ARSE activity inhibition was observed starting at concentrations of 10 I~M and was almost complete at 5 mM (15% activity). ARSC was not affected by the presence of warfarin in the incubation mixture.
homologous loci MIC2, MIC2R, and PBDX (Smith and Goodfellow, 1994 ). An obligatory crossing-over event occurs in this region of the X and Y chromosomes at each male meiosis, and this extremely high frequency of recombination may render this region more prone to unequal crossing-over, leading to deletions and duplications. The ARSD, ARSE, and ARSF loci are located only 150 kb from the pseudoautosomal boundary. We propose that this A profound deficiency of a heat-labile neutral arylsulfatase activity was observed in patients with deletions spanning the CDPX critical region. In patients with XLI, this activity is normal. The CDPX patient has normal ARSC and STS activities, while both activities are deficient in MSD and XLI/ CDPX patients.
cluster of three genes was generated by unequal crossingover events that occurred in an ancestral pseudoautosomal region. The repositioning of the pseudoautosomal boundary more telomeric on Xp may have allowed the X and Y copies of these genes to diverge, with subsequent loss of function of the Y copies. A similar mechanism was proposed for the STS and KAL genes (Yen et al., 1988; del Castillo et al., 1992; Incerti et al., 1992) . The finding that at least two of these novel genes (ARSD and ARSE) escape X inactivation, as well as the detection of homologous loci on the Y chromosome, supports this hypothesis. The identification of three genes from the CDPX critical region encoding putative sulfatases suggested the possibility that CDPX was due to a sulfatase deficiency. The observation of at least two patients with MSD who had typical radiological and facial features of CDPX, one presenting at birth (Burch et al., 1986) and the other who died in utero (J. Hopwood, personal communication), strongly supports this hypothesis. As features of CDPX are relatively mild, compared with the other features of MSD, and tend to fade with age, they may have been overlooked in other cases with MSD.
The ARSE Gene Is Mutated in CDPX As ARSD, ARSE, and ARSF genes are all located within the CDPX critical region, it was difficult to establish which one of these three genes was specifically involved in the pathogenesis of CDPX. The presence of substantial sequence divergence among these three genes, as shown by lack of cross-hybridization, suggests that they may have a different function as the result of a different substrate specificity. This is also supported by the presence of different expression patterns, ARSD being quite ubiquitously expressed and ARSE being expressed exclusively in liver, pancreas, and kidney.
We searched for point mutations in both ARSD and ARSE genes in a heterogeneous group of 27 unrelated male patients displaying features of CDPX. Five missense mutations in the ARSE gene were identified. One can suggest that these mutations are related to the occurrence of CDPX on the basis of the following observations. None of the mutations were found in any of 60 normal female individuals, corresponding to 120 normal X chromosomes. Some of the mutations resulted in nonconservative amino acid substitutions, such as the R111P mutation changing a basic amino acid to a (turn inducer) neutral hydrophobic one, or the G137V changing a polar amino acid to a hydrophobic one. This latter mutation, located in a highly conserved domain, substitutes a glycine residue that is found at the same position in all previously described sulfatases in human and other species, including E. coli (Daniels et al., 1992) and K. aerogenes (Murooka et al., 1990) . Furthermore, a mutation in a different sulfatase gene, ARSB, resulting in a glycine to valine substitution at exactly the same position was described by Wicker et al. (1991) in a patient with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). This mutation severely impaired the processing and stability of ARSB precursor polypeptides that are not converted to mature ARSB and undergo rapid proteolytic degradation, as shown by the analysis of fibroblasts from the patient and by the expression of this mutation in LTK-cells. These authors speculated that the glycine at position 137 is of crucial importance for the secondary structure of the arylsulfatases, since it appears to be located at a junction between an ~ helix and a 13 sheet (Wicker et al., 1991) .
These data implicate ARSE in the pathogenesis of CDPX. The fact that we could detect ARSE mutations in only a fraction of all patients with the CDPX phenotype referred to us for molecular analysis would be consistent with the presence of genetic heterogeneity for CDPX. Since only 9 out of 11 exons of the ARSE gene have been screened for mutations, additional mutations may be found in the remaining two exons (exons 1 and 2). Furthermore, we cannot exclude the possibility that mutations in the ARSD or ARSF genes may also cause CDPX.
CDPX Due to ARSE Deficiency
Previous studies reported data suggesting the presence of two variants of ARSC based on both electrophoresis and immunoprecipitation studies. These two variants were designated F (faster migrating) and S (slowly migrating). Only the latter of these two variants appeared to correspond to STS, the other being a separate entity (Chang et al., 1990) . We have identified a gene encoding an arylsulfatase with the same biochemical features and tissue distribution of the previously reported "F form" of ARSC. Expression of ARSE cDNA in COS cells demonstrated that ARSE is heat labile, has a neutral pH optimum (data not shown), is inactive against steroid sulfates, and is not competitively inhibited by them. Enzyme analysis of fibroblasts from patients with CDPX carrying deletions spanning the ARSE gene and from patients with MSD demonstrated a deficiency of a heat-labile arylsulfatase activity that, most likely, corresponds to the product of the ARSE gene. Together, these data indicate that CDPX is an inborn error of metabolism due to deficiency of ARSE.
Physiological Role of ARSE and the Warfarin Embryopathy
Warfarin, a coumarin derivative that inhibits vitamin K reductase activity (Fasco et al., 1982) , interferes with normal cartilage and bone development. Warfarin embryopathy, a well-known human teratologic syndrome that is the con. sequence of maternal use of warfarin between 6 and 9 postconceptual weeks (Hall et al., 1980) , results in skeletal and facial abnormalities strikingly similar to those of CDPX (Pauli, 1988) . Rats treated with warfarin develop skeletal changes characterized by excessive mineralization and growth plate closure of long bones, associated with snout dysmorphisms (Price, 1985; Howe and Webster, 1992) . A phenocopy of CDPX and of warfarin embryopathy is the congenital deficiency of vitamin K epoxide reductase, the enzyme recycling vitamin K epoxide to vitamin K (Pauli et al., 1987) . These observations indicate the importance of vitamin K in bone and cartilage development. This is further emphasized by the involvement of vitamin K in the carboxylation of bone Gla protein and of matrix Gla pro. tein, two essential components of bone and cartilage (Price, 1985) . The striking similarities among CDPX, warfarin embryopathy, and vitamin K epoxide reductase deficiency phenotypes and the evidence that warfarin inhibits ARSE both suggest that these disorders are due to abnormalities in the same metabolic pathway. However, since warfarin concentrations required for inhibition of ARSE activity are high, we cannot rule out the possibility that ARSE is not the direct target of the drug in warfarin embryopathy.
The physiological role of ARSE and the mechanisms by which its deficiency leads to the skeletal changes typical of CDPX are not understood. A major unresolved issue is the identity of the natural substrate for ARSE. The nature of the CDPX phenotype suggests that ARSE may be essential for the correct composition of cartilage and bone matrix during bone development. The importance of several lysosomal sulfatases in cartilage and bone development is evident from their involvement in the catabolic pathway of sulfated glycosaminoglycans, which are essential components of the extracellular matrix of cartilage. Accordingly, bone and cartilage abnormalities are present in other sulfatase deficiencies, such as in mucopolysaccharidoses type II, IIID, IVA, and VI (Neufeld and Muenzer, 1995) . However, differences in pH optima between ARSE and lysosomal sulfatases indicate that they have different subcellular localization and, therefore, different metabolic functions. The recent finding of a sulfate transport defect in diastrophic dysplasia, an osteochondrodysplasia that is characterized by dwarfism, spinal deformation, and joint abnormalities, further emphasizes the importance of sul-fate metabolism in cartilage and bone development (H&st-backa et al., 1994) .
In conclusion, our data suggest that a sulfatase deficiency is responsible for bone and cartilage changes in both genetic and drug-induced human disorders. Further studies are needed to characterize the relative roles of ARSE and vitamin K in bone and cartilage development and to understand fully the metabolic pathway that is impaired in CDPX and in warfarin ernbryopathy.
Experimental Procedures Patients and Cell Lines
The 27 patients (23 sporadic and 4 familial) tested for point mutations in the ARSD and ARSE genes had the typical radiological and clinical features of CDPX. Some of these patients have been described in previous reports (Sheffield et al., 1976; Maroteaux, 1989) . Patient PAR492, in whom the G137V mutation was identified, corresponds to case 1 in a previous report (Maroteaux, 1989) . Fibroblast cell lines BA65, BA67, BA88, and BA16 are from patients with X-linked ichthyosis (XLI) carrying a deletion of the STS gene. BA311 is from a patient with CDPX carrying an X/Y translocation involving the Xp22.3 region (Wang et al., 1995) . BA428 cell line (Burch et al., 1986 ), a gift from Dr. Fensom, and BA426, obtained from the Human Mutant Cell Repository (cell line GM3245), are from patients with MSD. BA20, BA423, and BA424 (Schaefer et al., 1993) are from patients with terminal Xp deletions involving both the CDPX and STS loci.
Physical Mapping
We have employed a previously described strategy to identify overlapping cosmid clones using entire YACs as probes (Wapenaar et al., 1994) . YAC clones spanning the CDPX region (Figure 1 ) are described in Wang et aL (1995) . Yeast DNA preparation, screening of the X-chromosome specific cosmid library using purified DNA from YACs NB6F12 and 455B10, and construction of cosmid contigs were performed as previously described (Wapenaar et al., 1994) . Two cosmid contigs, spanning 340 kb of the CDPX critical region (with a gap of 60 kb), were assembled.
Exon Amplification
Four cosmid clones belonging to the first contig (clones 16, 76, 75, and 48) and five belonging to the second ~clones 32, 66, 58, 96, and 100) were used for exon amplification experiments. The cosmid clones were individually digested with BamHI-Bglll, cloned in the pSPL3 vector, and used for the exon amplification experiments as previously described (Church et al., 1994) .
Screening of eDNA Libraries
An adult human kidney cDNA library, oligo(dT) + random primed (Clontech HL1123n), was plated at a density of 1 x 106 PFU and screened using exon amplification products as probes. Hybridization and washing conditions were as previously described (Franco et al., 1991) . To validate the 5' end of ARSD transcript, 5'-RACE-PCR was performed as previously described (Frohman et al., 1988) .
DNA Sequence Analysis
Consensus cDNA sequences spanning the entire coding regions of the ARSD and ARSE genes were obtained by end sequencing of overlapping cDNA clones and by primer walking. Sequencing was performed either man ually, using a Seq uenase Version 2.0 DNA Sequencing kit (United States Biochemical), or automatically, using an Applied Biosystem ABI 373A fluorescence sequencer. Assembly and analysis of DNA sequences were performed using the facilities of the Molecular Biology Information Resource, Department of Cell Biology, Baylor College of Medicine. Data base searches were carried out using the GCG software package and the BLAST network service from the National Center for Biotechnology Information. The multiple sequence alignment shown in Figure 2 was performed using the pattern-induced multisequenoe alignment (PIMA) algorithm (Smith and Smith, 1992) .
mRNA Analysis
Northern blots containing human RNAs from several tissues were purchased from Clontech and hybridized to exons 76.15 and 48.7 from the ARSD and ARSE genes, respectively, using the conditions recommended by the manufacturer (Clontech). Washing conditions were 0.1 x SSC, 0.2% SDS at 50°C for both probes. Fibroblasts from a normal male individual and a somatic cell hybrid (BA342) retaining the inactive X chromosome were used for the X inactivation studies. RT-PCR experiments were performed as previously described (Borsani et al., 1991) . The following oligonucleotide primers were used: ARSD F, GAGGAAGGTGTGAGGCTC; ARSD R, CCTGAGCCTGCG-I-rCCACTG; ARSE F, GTCTCAACTGTGAGTCAG; ARSE R, AAGTT-CTCCATAGTGATAA.
PCR was carried out for 40 cycles. Annealing temperatures were 50°C for ARSD and ARSE primers. MIC2 and PGK1 PCR conditions and primers were as previously described (Brown et al., 1990; Franco et al., 1991) .
SSCP Analysis
SSCP analysis was performed on amplified genomic DNA from patients according to a previously described method (Orita et al., 1989) . Direct sequencing was carried out on PCR products purified from a 2% low melting agarose gel (Nusieve FMC), using a Sequenase 2.0 kit (United States Biochemical).
Expression of ARSC and ARSE in Eukaryotic Cells
ARSC/STS cDNA (Ballabio et al., 1987) was subcloned in EcoRIdigested plasmid pcDL-SRa296 (Takebe et al., 1988) . ARSE cDNA, obtained by ligating two different cDNA clones, was blunt ended and subcloned in the same vector. COS cells were transfected with 10-20 I~g of either construct by electi'oporation and harvested by trypsinization 48-76 hr after transfection for enzyme assays.
Enzyme Assays
Fibroblast extracts were prepared as previously described (Chang et al, 1985) . COS cells were resuspended in 0.1 M Tris-HCI (pH 7.5), 1% Triton X-100, and 150 mM NaCI. Neutral arylsulfatase activity assay conditions were as follows: the incubation mixture (200 p.I) contained 30-40 I~g of protein, 0.2 mmol/I 4-MU sulfate, in 0.05 M Tris-HCI buffer (pH 7.5). The enzymatic assay was run at 37°C for 4 hr. The reaction was stopped by adding 1.8 ml of glycine-carbonate buffer (pH 10.7), and fluorescence was determined at 365 nm (excitation) and 460 nm (emission) on a Hoefer TKO 100 fluorometer. Warfarin inhibition analysis was performed by adding 3-(~z-acetonylbenzyl)-4-hydroxycoumarin (warfarin) sodium salt (Sigma A-3430) at different concentrations to the incubation mix.
To measure heat-labile, non-STS, arylsulfatase activity, part of the fibroblast extract was inactivated for 15 rain at 50°C, while the noninactivated samples were kept in ice. The assay was performed in the presence of 0.6 mmol/I DHEA sulfate (DHEAS) in the incubation mixture. The enzymatic activity was calculated as the difference between the activities of heat-inactivated and noninactivated samples. DHEA and estrone sulfatase activities were measured as previously described (Ballabio et al., 1985; Munroe and Chang, 1987) .
